E-ISSN 2149-388X | ISSN 2149-0430
 

Original Research (Original Article) 


At what Point is HPV in Cervical Cancer Screening?

Pervin Karli.

Abstract
Background: Cervical cancer is the third most frequently seen cancer type after colorectal and breast cancers. It takes the fourth place with respect to mortality rate among the cancers seen in women. The aim of this study is to investigate the association of HPV with cervical premalignant lesions and the type of premalignant lesion seen.
Materials and Methods: The study was conducted in the province of Amasya, Turkey between August 2014 and December 2017 with 24,446 women aged between 30 and 65 years of age, by co-test screening using HPV and cervical cytology in combination.
Results: HPV was found at a rate of 26%, HPV18 at a rate of 16.5%, HPV outside 16-18 at a rate of 68.6% and HPV 16-18 combination at a rate of 0.4%. The cytological results of 724 HPV-positive patients revealed that 24.3% were normal, 5.8% had ASC-US, 8% LGSIL, 0.3% HGSIL, 0.3% ASC-H, 0.4% AGC, 45% infection, and 15.9% had insufficient material.
Conclusion: This study demonstrates which cytological findings we mostly encounter HPV. The HPV screening revealed that the HPV types outside HPV16-18 constituted a large majority and a considerable amount of accompanying cytological abnormalities was present. In conclusion, the possibility of other HPV types to cause cervical premalignant lesions and thus their association with cervical cancer is shown to be negligible.

Key words: HPV, cervical screening test, HSIL, LSIL, ASC-US


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Pervin Karli
on Google
on Google Scholar
Article Statistics
 Viewed: 150
Downloaded:
Cited: 0

How to Cite this Article
Pubmed Style

Pervin Karli. At what Point is HPV in Cervical Cancer Screening?. Ulutas Med J. 2018; 4(4): 227-231. doi:10.5455/umj.20180916094458


Web Style

Pervin Karli. At what Point is HPV in Cervical Cancer Screening?. http://www.ulutasmedicaljournal.com/?mno=8738 [Access: January 22, 2019]. doi:10.5455/umj.20180916094458


AMA (American Medical Association) Style

Pervin Karli. At what Point is HPV in Cervical Cancer Screening?. Ulutas Med J. 2018; 4(4): 227-231. doi:10.5455/umj.20180916094458



Vancouver/ICMJE Style

Pervin Karli. At what Point is HPV in Cervical Cancer Screening?. Ulutas Med J. (2018), [cited January 22, 2019]; 4(4): 227-231. doi:10.5455/umj.20180916094458



Harvard Style

Pervin Karli (2018) At what Point is HPV in Cervical Cancer Screening?. Ulutas Med J, 4 (4), 227-231. doi:10.5455/umj.20180916094458



Turabian Style

Pervin Karli. 2018. At what Point is HPV in Cervical Cancer Screening?. THE ULUTAS MEDICAL JOURNAL, 4 (4), 227-231. doi:10.5455/umj.20180916094458



Chicago Style

Pervin Karli. "At what Point is HPV in Cervical Cancer Screening?." THE ULUTAS MEDICAL JOURNAL 4 (2018), 227-231. doi:10.5455/umj.20180916094458



MLA (The Modern Language Association) Style

Pervin Karli. "At what Point is HPV in Cervical Cancer Screening?." THE ULUTAS MEDICAL JOURNAL 4.4 (2018), 227-231. Print. doi:10.5455/umj.20180916094458



APA (American Psychological Association) Style

Pervin Karli (2018) At what Point is HPV in Cervical Cancer Screening?. THE ULUTAS MEDICAL JOURNAL, 4 (4), 227-231. doi:10.5455/umj.20180916094458